• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Berlex to sell prefilled Magnevist syringes

Article

Montville, NJ-based Berlex Laboratories has received Food and Drug Administration approval to market its Magnevist MRI contrast agent in prefilled syringes. The contrast company expects to begin shipments of the syringes in the first quarter of 1999.

Montville, NJ-based Berlex Laboratories has received Food and Drug Administration approval to market its Magnevist MRI contrast agent in prefilled syringes. The contrast company expects to begin shipments of the syringes in the first quarter of 1999. Prefilled syringes will come in 10-mL, 15-mL, and 20-mL sizes. Berlex believes that prefilled syringes will save time and reduce the potential for contamination and needle stick incidents that might occur when Magnevist syringes are filled manually.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.